吉西他滨联合替吉奥治疗蒽环类耐药晚期乳腺癌的效果
|
摘要
目的探讨吉西他滨联合替吉奥治疗蒽环类耐药晚期乳腺癌的效果。方法选取2015年8月～2017年8月我院收治的60例蒽环类耐药晚期乳腺癌患者作为研究对象,按照治疗方法的不同,将其分为对照组(30例)与观察组(30例)。对照组患者采用吉西他滨注射液,观察组患者采用吉西他滨联合替吉奥方案。比较两组患者的治疗总有效率、毒副作用发生率和治疗前后卡氏(KPS)评分与数字评分法(NRS)评分。结果观察组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者的毒副作用Ⅰ级发生率为33.3%,毒副作用Ⅱ级发生率为40.0%,高于对照组的10.0%和16.3%,毒副作用Ⅲ级发生率低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前的KPS评分、NRS评分比较,差异无统计学意义(P>0.05);观察组患者治疗后的KPS评分明显高于对照组,NRS评分明显低于对照组,差异有统计学意义(P<0.05)。结论蒽环类耐药晚期乳腺癌患者使用吉西他滨联合替吉奥治疗方案,临床效果好,毒副作用小,可改善体力状况,缓解疼痛感,值得深入研讨,并在此基础上展开推广应用。
Objective To investigate the efficacy of Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium in the treatment of Anthracycline resistant advanced breast cancer. Methods A total of 60 patients with Anthracycline resistant advanced breast cancer admitted in our hospital from August 2015 to August 2017 were selected as subjects.According to different treatment methods, they were divided into control group(30 cases) and observation group(30 cases). The control group was treated with Gemcitabine Injection. The observation group was treated with Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium. The total effective rate, toxic side effect rate, Kamofsky performance status(KPS) score and numerical raing scale(NRS) score before and after treatment were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the significance of calculation was significant(P<0.05). The incidence of side effects Ⅰ level in the observation group was33.3%, the incidence of toxic side effects Ⅱ level was 40.0%, which were higher than those of the control group(10.0% and 16.3%), the incidence of toxic side effects Ⅲ level was lower than that in the control group, the differences were statistically significant(P<0.05). There was no significant difference in KPS score and NRS score between the two groups before treatment(P>0.05), but the KPS score in the observation group was significantly higher than that in the control group, and the NRS score in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Anthracycline resistant advanced breast cancer patients using Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium treatment regimen, the clinical effect is good, the toxic side effects are small, can improve physical conditions, alleviate the pain, it is worth in-depth research, and on this basis to promote the application.
Objective To investigate the efficacy of Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium in the treatment of Anthracycline resistant advanced breast cancer. Methods A total of 60 patients with Anthracycline resistant advanced breast cancer admitted in our hospital from August 2015 to August 2017 were selected as subjects.According to different treatment methods, they were divided into control group(30 cases) and observation group(30 cases). The control group was treated with Gemcitabine Injection. The observation group was treated with Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium. The total effective rate, toxic side effect rate, Kamofsky performance status(KPS) score and numerical raing scale(NRS) score before and after treatment were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the significance of calculation was significant(P<0.05). The incidence of side effects Ⅰ level in the observation group was33.3%, the incidence of toxic side effects Ⅱ level was 40.0%, which were higher than those of the control group(10.0% and 16.3%), the incidence of toxic side effects Ⅲ level was lower than that in the control group, the differences were statistically significant(P<0.05). There was no significant difference in KPS score and NRS score between the two groups before treatment(P>0.05), but the KPS score in the observation group was significantly higher than that in the control group, and the NRS score in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Anthracycline resistant advanced breast cancer patients using Gemcitabine combined with Tegafur Gimeracil Oteracil Potassium treatment regimen, the clinical effect is good, the toxic side effects are small, can improve physical conditions, alleviate the pain, it is worth in-depth research, and on this basis to promote the application.
引文
[1]王佳,郝飞,付诗.微信平台在乳腺癌术后输液港化疗患者延伸护理中的应用[J].护理学杂志,2016,31(8):91-93.
[2]张守文,张小霞,石增成,等.卡维地洛联合曲美他嗪对接受含蒽环类药物化疗乳腺癌患者的心脏保护作用[J].中国全科医学,2016,19(7):794-798.
[3]郭永强,马东红,贾国柱.卡培他滨联合吉西他滨治疗蒽环类耐药的转移性乳腺癌的效果比较[J].中国保健营养,2016,26(15):246-247.
[4]左婷婷,陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床,2016,43(14):639-642.
[5]徐兵河,江泽飞,胡夕春.中国晚期乳腺癌临床诊疗专家共识2016[J].中华医学杂志,2016,96(22):1719-1727.
[6]李光明,段百芸.托瑞米芬联合他莫昔芬应用于晚期乳腺癌治疗效果及生存质量分析[J].中国普通外科杂志,2016,25(3):463-466.
[7]廖静,李戈,张熔.急性淋巴细胞白血病患儿MTHFR基因多态性与大剂量甲氨蝶呤毒副反应的相关性[J].肿瘤预防与治疗,2016,29(3):144-148.
[8]潘晓明,白昱旸,杨小清,等.化疗前口服减毒汤对乳腺癌术后AC→T方案化疗耐受性影响观察[J].世界中西医结合杂志,2017,12(4):557-560.
[9]张亚峰,王鹏.卡培他滨单药或联合方案治疗乳腺癌骨转移的临床疗效观察[J].实用癌症杂志,2017,32(12):2045-2048.
[10]童雅兰,韩涛,宋树玺,等.阿瑞匹坦三联用药预防乳腺癌蒽环类药物联合环磷酰胺化疗致恶心呕吐的效果观察[J].临床误诊误治,2016,29(4):83-86.
[11]李琪,赵峻峰,史晓宇,等.阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察[J].河北医科大学学报,2017,38(12):1384-1387.
[12]李莉,王友群,孙蔚莉,等.含铂方案治疗晚期乳腺癌临床研究[J].中华肿瘤防治杂志,2016,23(10):657-662.
[13]乔红梅,陈亮,丁富强.CEA、CA125、CA15-3在吉西他滨治疗乳腺癌化疗前后的表达及意义[J].癌症进展,2017,15(8):926-928.
[14]王洪涛,黄远丽,董超,等.吉西他滨或长春瑞滨联合顺铂治疗转移性三阴性乳腺癌的疗效比较[J].现代中西医结合杂志,2017,26(2):164-166.
[15]张艳芳,牛春莲,张春珍,等.吉西他滨联合紫杉醇周方案治疗蒽环类耐药的晚期乳腺癌疗效观察[J].中国实用医刊,2016,43(13):51-53.
[16]焦洋,宁洁,王芳,等.晚期乳腺癌替吉奥与卡培他滨治疗疗效及安全性对比研究[J].中华肿瘤防治杂志,2016,23(7):452-456.
[17]王建青,余小红,肖遥.中药浴足联合替吉奥维持治疗转移性乳腺癌的临床观察[J].现代中西医结合杂志,2016,25(3):277-279.
[18]屈淑贤,郑振东,刘兆喆,等.吉西他滨联合替吉奥胶囊三线治疗转移性三阴乳腺癌的疗效和安全性[J].中华内分泌外科杂志,2015,9(1):41-44.
[19]覃文办,李永标,唐超莉,等.TACE联合替吉奥治疗原发性肝癌的近期疗效、毒副作用及生存情况观察[J].中国医药导报,2017,14(23):71-74,79.
[20]聂力,邵腾飞,葛卫红.替吉奥单药联合西药强调放疗同步治疗老年晚期非小细胞肺癌的效果[J].中国医药导报,2017,14(17):4-7.
[21]陈珑,王琳,何冬雷,等.替吉奥联合小牛脾提取物注射液治疗中晚期胃鳞癌的效果和安全性[J].中国医药导报,2018,15(20):130-134.
[22]谢林浩,刘驯炎.SOX或DCF方案一线化疗联合替吉奥维持治疗晚期胃癌的疗效及临床研究[J].中国医药科学,2017,7(12):11-14.
[23]冯卫能,张华,陈泽程,等.吉西他滨联合替吉奥对比吉西他滨单药三线治疗晚期非小细胞肺癌的疗效及安全性[J].中国医药科学,2017,7(9):28-31.
[2]张守文,张小霞,石增成,等.卡维地洛联合曲美他嗪对接受含蒽环类药物化疗乳腺癌患者的心脏保护作用[J].中国全科医学,2016,19(7):794-798.
[3]郭永强,马东红,贾国柱.卡培他滨联合吉西他滨治疗蒽环类耐药的转移性乳腺癌的效果比较[J].中国保健营养,2016,26(15):246-247.
[4]左婷婷,陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床,2016,43(14):639-642.
[5]徐兵河,江泽飞,胡夕春.中国晚期乳腺癌临床诊疗专家共识2016[J].中华医学杂志,2016,96(22):1719-1727.
[6]李光明,段百芸.托瑞米芬联合他莫昔芬应用于晚期乳腺癌治疗效果及生存质量分析[J].中国普通外科杂志,2016,25(3):463-466.
[7]廖静,李戈,张熔.急性淋巴细胞白血病患儿MTHFR基因多态性与大剂量甲氨蝶呤毒副反应的相关性[J].肿瘤预防与治疗,2016,29(3):144-148.
[8]潘晓明,白昱旸,杨小清,等.化疗前口服减毒汤对乳腺癌术后AC→T方案化疗耐受性影响观察[J].世界中西医结合杂志,2017,12(4):557-560.
[9]张亚峰,王鹏.卡培他滨单药或联合方案治疗乳腺癌骨转移的临床疗效观察[J].实用癌症杂志,2017,32(12):2045-2048.
[10]童雅兰,韩涛,宋树玺,等.阿瑞匹坦三联用药预防乳腺癌蒽环类药物联合环磷酰胺化疗致恶心呕吐的效果观察[J].临床误诊误治,2016,29(4):83-86.
[11]李琪,赵峻峰,史晓宇,等.阿帕替尼联合化疗用于二线治疗失败晚期卵巢癌的临床观察[J].河北医科大学学报,2017,38(12):1384-1387.
[12]李莉,王友群,孙蔚莉,等.含铂方案治疗晚期乳腺癌临床研究[J].中华肿瘤防治杂志,2016,23(10):657-662.
[13]乔红梅,陈亮,丁富强.CEA、CA125、CA15-3在吉西他滨治疗乳腺癌化疗前后的表达及意义[J].癌症进展,2017,15(8):926-928.
[14]王洪涛,黄远丽,董超,等.吉西他滨或长春瑞滨联合顺铂治疗转移性三阴性乳腺癌的疗效比较[J].现代中西医结合杂志,2017,26(2):164-166.
[15]张艳芳,牛春莲,张春珍,等.吉西他滨联合紫杉醇周方案治疗蒽环类耐药的晚期乳腺癌疗效观察[J].中国实用医刊,2016,43(13):51-53.
[16]焦洋,宁洁,王芳,等.晚期乳腺癌替吉奥与卡培他滨治疗疗效及安全性对比研究[J].中华肿瘤防治杂志,2016,23(7):452-456.
[17]王建青,余小红,肖遥.中药浴足联合替吉奥维持治疗转移性乳腺癌的临床观察[J].现代中西医结合杂志,2016,25(3):277-279.
[18]屈淑贤,郑振东,刘兆喆,等.吉西他滨联合替吉奥胶囊三线治疗转移性三阴乳腺癌的疗效和安全性[J].中华内分泌外科杂志,2015,9(1):41-44.
[19]覃文办,李永标,唐超莉,等.TACE联合替吉奥治疗原发性肝癌的近期疗效、毒副作用及生存情况观察[J].中国医药导报,2017,14(23):71-74,79.
[20]聂力,邵腾飞,葛卫红.替吉奥单药联合西药强调放疗同步治疗老年晚期非小细胞肺癌的效果[J].中国医药导报,2017,14(17):4-7.
[21]陈珑,王琳,何冬雷,等.替吉奥联合小牛脾提取物注射液治疗中晚期胃鳞癌的效果和安全性[J].中国医药导报,2018,15(20):130-134.
[22]谢林浩,刘驯炎.SOX或DCF方案一线化疗联合替吉奥维持治疗晚期胃癌的疗效及临床研究[J].中国医药科学,2017,7(12):11-14.
[23]冯卫能,张华,陈泽程,等.吉西他滨联合替吉奥对比吉西他滨单药三线治疗晚期非小细胞肺癌的疗效及安全性[J].中国医药科学,2017,7(9):28-31.